Gemzar treatment is now considered the standard of care for pancreatic cancer following surgery.
吉西他滨目前是作为胰腺癌术后的标准治疗药物。
Gemzar is the first drug approved by the FDA in more than 30 years for the treatment of patients with advanced pancreatic carcinoma.
健择是30年来美国FDA首次批准的用于治疗晚期胰腺癌的有效药物。
The median survival for patients taking both Avastin and Gemzar was 5.7 months compared with 6.0 months for patients taking Gemzar alone.
吉西他滨合用贝伐单抗的患者中位生存期为5.7个月，而单用吉西他滨者为6个月。
The study researchers assigned 302 patients to receive Avastin and Gemzar and assigned an additional 300 patients to receive Gemzar plus placebo.
该研究中，302名患者接受吉西他滨合用贝伐单抗，300名患者接受吉西他滨和安慰剂。
CONCLUSION: Kanglaite combined with Gemzar could inhibit the growth of the transplanted human pancreatic carcinoma in nude mice and has synergistic effect.
结论：康莱特注射液与健择对移植于裸鼠的人胰腺癌的抑制作用具有协同效应。
CONCLUSION: Kanglaite combined with Gemzar could inhibit the growth of the transplanted human pancreatic carcinoma in nude mice and has synergistic effect.
结论：康莱特注射液与健择对移植于裸鼠的人胰腺癌的抑制作用具有协同效应。
应用推荐